BLA 103780 · Serono INC
Rebif
Interferon Beta-1a · Interferon beta
NovelLast checked: Nov 20, 2026Latest source record: Jul 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Mar 7, 2002
Approved uses
5
Original approval plus efficacy supplements
Registered trials
165
55 Phase 3, 3 recruiting
FAERS reports
47,980
36,921 serious, 2,806 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 22, 2025.
REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Rebif is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Mechanism: The mechanism(s) by which REBIF (interferon beta-1a) exerts its therapeutic effects in patients with multiple sclerosis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 26, 2020 Supplement 5203 · Efficacy LabelLetter
- Sep 27, 2016 Supplement 5196 · Efficacy LabelLetterReview
- Mar 26, 2004 Supplement 5027 · Efficacy
- May 2, 2003 Supplement 5010 · Efficacy LabelReviewLetter
- Mar 7, 2002 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
2 products under this application
- REBIF · INTERFERON BETA-1A 44UG/0.5ML · SYRINGE, · Prescription
- REBIF · INTERFERON BETA-1A 22UG/0.5ML · SYRINGE, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Interferon Beta-1a" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT01064401 · 1,841 participants · Start May 2010 · Primary completion Mar 2014
Drug: BIIB019 (Daclizumab High Yield Process); Interferon beta-1a Placebo and 2 more · For: Relapsing-Remitting Multiple Sclerosis
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 228 sites in all
- Trial of Treatments for COVID-19 in Hospitalized AdultsPivotal-lookingCompleted
Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
NCT04315948 · 1,552 participants · Start Mar 22, 2020 · Primary completion Jul 9, 2022
Drug: Remdesivir; Lopinavir/ritonavir and 3 more · For: Corona Virus Infection
Sites: Innsbruck, Austria; Linz, Austria; Salzburg, Austria · 62 sites in all
- Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00906399 · 1,516 participants · Start Jun 2009 · Primary completion Oct 2012
Drug: BIIB017 (peginterferon beta-1a); Placebo · For: Relapsing Multiple Sclerosis
Sites: Phoenix, Arizona; Ponte Vedra Beach, Florida; Atlanta, Georgia · 178 sites in all
- Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)Pivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02294058 · 1,346 participants · Start Dec 3, 2014 · Primary completion Dec 22, 2016
Drug: Ozanimod; Interferon beta-1a and 2 more · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Tucson, Arizona; Berkeley, California · 224 sites in all
- BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)Pivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT00605215 · 1,331 participants · Start Apr 24, 2008 · Primary completion Jun 10, 2011
Drug: Laquinimod; Placebo and 1 more · For: Multiple Sclerosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 170 sites in all
- Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02047734 · 1,320 participants · Start Dec 3, 2013 · Primary completion Mar 27, 2017
Drug: Ozanimod; Ozanimod placebo and 2 more · For: Relapsing Multiple Sclerosis
Sites: Phoenix, Arizona; Tucson, Arizona; Berkeley, California · 299 sites in all
- An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00930553 · 1,314 participants · Start Aug 2009 · Primary completion Feb 2016
Drug: alemtuzumab · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Cullman, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 176 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- multiple sclerosis relapse4,095
- fatigue2,997
- injection site erythema2,959
- influenza like illness2,933
- fall2,554
- headache2,455
- injection site pain2,431
- pain1,939
- depression1,846
- multiple sclerosis1,784
- gait disturbance1,767
- hypoaesthesia1,654
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 314 |
| 2005 | 1,651 |
| 2006 | 571 |
| 2007 | 1,652 |
| 2008 | 2,032 |
| 2009 | 2,506 |
| 2010 | 3,611 |
| 2011 | 4,468 |
| 2012 | 4,809 |
| 2013 | 5,832 |
| 2014 | 3,083 |
| 2015 | 1,901 |
| 2016 | 1,806 |
| 2017 | 1,965 |
| 2018 | 1,969 |
| 2019 | 1,970 |
| 2020 | 1,537 |
| 2021 | 1,814 |
| 2022 | 1,632 |
| 2023 | 1,055 |
| 2024 | 790 |
| 2025 | 637 |
| 2026 | 375 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rebif (Interferon Beta-1a/Albumin)
2024 spending
$105M
Beneficiaries
1,048
9,289 claims
Per beneficiary
$100,551
$1,768.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $232,708,461 |
| 2021 | $198,665,888 |
| 2022 | $162,331,588 |
| 2023 | $131,300,521 |
| 2024 | $105,377,037 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L, Wolinsky JS, Giovannoni G, et al. · JAMA Neurol 2020 · Clinical Trial, Phase III, Multicenter Study
- Multiple sclerosis clinical decision support system based on projection to reference datasets.
Ed-Driouch C, Chéneau F, Simon F, et al. · Ann Clin Transl Neurol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization.
De Stefano N, Giorgio A, Gentile G, et al. · Ann Clin Transl Neurol 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Serono INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.